Channel Therapeutics Corporation
CHRO · AMEX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.70 | -0.00 | 1.88 | -0.27 |
| FCF Yield | -22.51% | -5.54% | -0.73% | -1.84% |
| EV / EBITDA | -3.92 | -3.19 | -89,388,611.80 | -17.18 |
| Quality | ||||
| ROIC | 0.00% | 77.11% | 108.36% | 345.66% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 50.00% |
| Cash Conversion Ratio | 0.94 | 0.13 | 0.32 | 0.35 |
| Growth | ||||
| Revenue 3-Year CAGR | 2,027,779.32% | 977,131.18% | 977,131.18% | 977,131.18% |
| Free Cash Flow Growth | -3,312.48% | 29.26% | 5.69% | -276.75% |
| Safety | ||||
| Net Debt / EBITDA | 0.79 | -0.70 | -2,372,091.00 | -0.75 |
| Interest Coverage | 0.00 | -14.78 | -13.72 | -16.90 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 97.07 | 0.00 | -1,206.01 | -187.05 |